A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease

Condition studied

Graves’ Disease

Investigational medicinal product(s)

Eligibility

Primary endpoint

Percentage of Group A Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52]

Endpoint detail

Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: At Week 26], Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: Up to Week 52], Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52], Time from Week 0 to the earliest date of confirmed relapse in Group B Participants [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52], Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52], Time From Week 0 to the earliest date of confirmed relapse in Group C Participants [Time Frame: Up to Week 52], Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb [Time Frame: At Week 26], Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb [Time Frame: Up to Week 52]